Publications by authors named "Kathy D Miller"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

494

Total Likes

166

Extended Reach

2,540,595

Social Features

89
C
Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening.
Christopher E Comstock, Constantine Gatsonis, Gillian M Newstead, Bradley S Snyder, Ilana F Gareen, Jennifer T Bergin, Habib Rahbar, Janice S Sung, Christina Jacobs, Jennifer A Harvey

JAMA· February 2020

Videos about Article: user user

2 87

View All Article and Social Media Activity
C
Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard?
Rina K Yadav, Kathy D Miller

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking Ribociclib Dosage and Use in the Era of Patient-Centered Oncology-When Less Is More.
Rina Yadav, Kathy D Miller

JAMA Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, Vandana G Abramson, Adam Brufsky, Kathy D Miller

J Natl Cancer Inst· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ: A Randomized Clinical Trial.
Seema A Khan, Justin Romanoff, Constantine Gatsonis, Habib Rahbar, Ruth Carlos, Kathy D Miller

JAMA Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance for Authors on Subgroup Representation and Reporting.
Stephanie B Wheeler, Alexia Iasonos, Iona Cheng, Charles Craddock, Kathy D Miller

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score.
Filipa Lynce, Samuel M Niman, Megumi Kai, Sean Ryan, Elizabeth Troll, Kathy D Miller

J Natl Cancer Inst· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.
Sneha Phadke, Kathy D Miller, Ami Shah, Oana C Danciu, Yi Chen

Breast Cancer Res Treat· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: De Novo Oligometastatic Breast Cancer.
Lajos Pusztai, Mariya Rozenblit, Peter Dubsky, Thomas Bachelot, Anna M Kirby, Kathy D Miller

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study.
Amy S Clark, Fengmin Zhao, Paula Klein, Alberto J Montero, Carla Falkson, Kathy D Miller

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.
Erika P Hamilton, Manish R Patel, Virginia F Borges, Jane L Meisel, Meena Okera, Kathy D Miller

Breast Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life Among Patients With Ductal Carcinoma In Situ.
Victoria J Dunsmore, Bradley S Snyder, Ilana F Gareen, Constance D Lehman, Seema A Khan, Kathy D Miller

JAMA Netw Open· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials.
Dario Trapani, Qingchun Jin, Kathy D Miller, Hope S Rugo, Katherine E Reeder-Hayes

Clin Breast Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer.
Lora Stojanovic, Rachel Abbotts, Kaushelendra Tripathi, Collin M Coon, Saranya Rajendran, Kathy D Miller

Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping the patient journey: Understanding oral anticancer medication use among patients diagnosed with breast cancer.
Yejin Seo, Karen Suchanek Hudmon, Kellie Jones Weddle, Yuehwern Yih, Kathy D Miller

J Oncol Pharm Pract· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer.
Catherine E Mosher, Shieun Lee, Elizabeth L Addington, Seho Park, Ashley B Lewson, Kathy D Miller

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D Miller

Front Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Couples in breast cancer survivorship: Daily associations in relationship satisfaction, stress, and health.
M Rosie Shrout, Megan E Renna, MiKaila J Leonard, Elliot M Friedman, Kathy D Miller

Compr Psychoneuroendocrinol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer.
Lora Stojanovic, Rachel Abbotts, Kaushlendra Tripathi, Collin M Coon, Saranya Rajendran, Kathy D Miller

bioRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D Miller

Front Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
Bryan P Schneider, Fengmin Zhao, Tarah J Ballinger, Sofia F Garcia, Fei Shen, Nadia Miller, Kathy D Miller

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Kathy D Miller

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia, Kathy D Miller

Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.
Fei Shen, Guanglong Jiang, Santosh Philips, Erica Cantor, Laura Gardner, Kathy D Miller

Br J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112.
Tarah J Ballinger, Helga S Marques, Gloria Xue, Richard Hoffman, Constantine Gatsonis, Kathy D Miller

J Natl Compr Canc Netw· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stromal heterogeneity may explain increased incidence of metaplastic breast cancer in women of African descent.
Brijesh Kumar, Aditi S Khatpe, Jiang Guanglong, Katie Batic, Poornima Bhat-Nakshatri, Kathy D Miller

Nat Commun· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis